MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
-$11,431K
(22.09%↑ Y/Y)
Federal
-$2,223K
(17.79%↑ Y/Y)
State
-$44K
(96.28%↑ Y/Y)
Qbrexza
$25,014K
Emrosi
$14,745K
Accutane
$12,882K
Foam Franchise
Products Amzeeq Zilxi
$5,859K
Other Legacy
$2,739K
Cutia Supply
Agreement
$606K
Royalties On Sales Of
Amzeeq By Cutia
$13K
Loss before income
taxes
-$11,371K
(22.18%↑ Y/Y)
Income tax expense
$60K
(-1.64%↓ Y/Y)
Total deferred
-$2,267K
(41.69%↑ Y/Y)
Product revenue, net
$61,239K
(11.07%↑ Y/Y)
Other revenue
$619K
(-38.10%↓ Y/Y)
Loss from operations
-$8,172K
(40.25%↑ Y/Y)
Total other expense
-$3,199K
(-242.51%↓ Y/Y)
Valuation allowance
$2,267K
(-41.71%↓ Y/Y)
Total revenue
$61,858K
(10.20%↑ Y/Y)
Interest income
$589K
(-22.19%↓ Y/Y)
Total current
$60K
(0.00%↑ Y/Y)
Total operating
expenses
$70,030K
(0.31%↑ Y/Y)
Interest expense
$3,698K
(36.96%↑ Y/Y)
Foreign exchange
transaction losses
-$90K
(22.41%↑ Y/Y)
State
$60K
(3.45%↑ Y/Y)
Selling, general and
administrative
$44,368K
(10.36%↑ Y/Y)
Cost of goods sold -
(excluding amortization of...
$20,924K
(0.22%↑ Y/Y)
Amortization of acquired
intangible assets
$4,258K
(24.36%↑ Y/Y)
Research and development
$480K
(-95.13%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Journey Medical Corp (DERM)
Journey Medical Corp (DERM)